Acute leukemia association with psoriasis: A report on 100 patients from a single center in China

The association between psoriasis and leukemia is a controversial topic. One hundred acute leukemia (AL) patients with psoriasis were divided into three groups according to treatment of psoriasis: (i) a bimolane treatment group (n = 35); (ii) a nonbimolane treatment group (n = 45); and (iii) an untreated group (n = 20). The most common type of leukemia associated with psoriasis was acute promyelocytic leukemia (APL). The proportion of nonrecurrent clonal chromosome structural aberration in the bimolane treatment group (42.9%) was significantly higher than that of the nonbimolane treatment group (17.1%) and the untreated group (21.4%; P < 0.05). In patients with non-APL, the complete remission rate of the first course in the nonbimolane treatment group (84.2%) was significantly higher than that of the bimolane treatment group (8.3%) and the untreated group (37.5%; P < 0.05). The 5-year overall survival rate (31.2%) and 5-year relapse-free survival rate (27.2%) in the bimolane group were lower than those of the nonbimolane treatment group (60.3%, 58.9%) and the untreated group (54.6%, 51.6%; P < 0.01). Nonrecurrent chromosome aberration (CA) was prone to occur in bimolane treated patients, who have lower remission rates and poor prognoses.